Bajaj Healthcare acquires GenRx Pharmaceuticals for manufacturing expansion

The acquisition is expected to be completed within 3–6 months, subject to requisite FDA and other regulatory approvals.

Incorporated in 2009 and headquartered in Thane, Maharashtra, GenRx Pharmaceuticals Private Limited is a WHO-GMP-certified pharmaceutical manufacturer engaged in the production of allopathic formulations, nutraceuticals, and natural products.

The company operates a manufacturing facility located at MIDC Sinnar, Nashik, with the capability to produce solid and semi-solid dosage forms such as tablets, capsules, external preparations, cosmetic products, and nasal sprays.

The development comes post-market hours. On Monday, shares of Bajaj Healthcare settled at ₹570 apiece on NSE, declining 3.96%. Its market capitalisation stood at ₹1,800.25 crore.

“The acquisition of GenRx Pharmaceuticals marks a strategic step forward in expanding our formulations manufacturing capabilities. This aligns with our vision of strengthening our core business and leveraging synergies for accelerated growth,” said Anil Jain, Managing Director of Bajaj Healthcare.

“This addition will enable us to expand our manufacturing portfolio, paving the way for long-term value creation and strengthening our footprint in the pharmaceutical sector,” Jain added.

Last week, Bajaj Healthcare’s Chief Financial Officer (CFO) Dayashankar Patel resigned from the company. Patel had stepped down citing personal reasons, and there is no material reason for the resignation.

For the October-December quarter of the previous fiscal year (Q3 FY25), Bajaj Healthcare posted a net profit of ₹11.7 crore as against a ₹2.2 crore net loss in the year-ago period. The company’s revenue from operations surged by 13.1% year-on-year (YoY) to ₹122.8 crore in the December quarter as compared to ₹108.6 crore in Q3 FY24 on the back of firm demand for its active pharmaceutical ingredients (APIs) and bulk drugs.

Bajaj Healthcare reported earnings before interest, taxes, depreciation, and amortisation (EBITDA) of ₹21.7 crore in Q3 FY25 as against ₹19.6 crore in the year-ago quarter, marking a 10.7% jump. Its EBITDA margin for the reporting quarter stood at 17.7%, marginally lower than 18.1% in the year-ago period.

Bajaj Healthcare is a leading pharma major engaged in the manufacturing of APIs, intermediates and formulations with a strong presence throughout the world. The company exports its APIs to over 50 countries.